Chair’s Take on Innovation in Prostate Cancer: Thoughts on New Evidence
In this activity, an expert in prostate cancer discusses recent developments in prostate cancer, including evidence presented at the 2020 ASCO Virtual Scientific Program, and offers thoughts on how to integrate a range of novel therapeutics and optimally navigate patient care for those with prostate cancer.
This activity has been designed to meet the educational needs of oncologists and other clinicians involved in the management of prostate cancer.
Upon completion of this activity, participants should be better able to:
- Examine the recent safety and efficacy data of emerging and available agents for metastatic castration-sensitive and non-metastatic castration-resistant prostate cancer
- Review the latest evidence and expert recommendations for selection and sequencing of approved therapies, including hormonal, anti-androgen, taxanes, and bone-directed therapies, alone or in combination for non-metastatic and metastatic prostate cancers
- Examine the role of genetic testing to better guide treatment decision-making throughout the prostate cancer continuum
- Summarize emerging evidence of monotherapy and combination strategies, including PARP and immune checkpoint inhibitor therapies, for the management of prostate cancer
- Plan evidence-based, personalized treatment algorithms, including the consideration of clinical trial enrollment, for patients with prostate cancer, based on disease-, patient-, and treatment-specific factors
PVI, PeerView Institute for Medical Education
Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.
PVI, PeerView Institute for Medical Education
Paige Davies has no financial interests/relationships or affiliations in relation to this activity.
Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.
Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.
Faculty and Disclosure / Conflict of Interest Policy
In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
William K. Oh, MD
Chief, Division of Hematology and Medical Oncology
Deputy Director, The Tisch Cancer Institute
Professor of Medicine and Urology
Ezra M. Greenspan, MD Professor in Clinical Cancer Therapeutics
Icahn School of Medicine at Mount Sinai
New York, New York
William K. Oh, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Foundry; Janssen Pharmaceuticals, Inc.; Sanofi; Sema4; and TeneoBio.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Penn State College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or C[email protected]. Reference course # G6635-20-T.
successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC Credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.
- 0.50 MOC
- 0.50 AMA PRA Category 1 Credit™
This course is offered through Penn State College of Medicine. To take this course you will be redirected to Penn State College of Medicine's website. You must have an account with Penn State College of Medicine in order to complete this activity.
Mocingbird continues to work with our CME partner network to provide courses directly to you. We appreciate your patience as we work toward that goal!